Antonella Savarese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonella Savarese has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Sandro Pignata
Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
3 shared publications - Domenica Lorusso
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
2 shared publications - Giorgio Bogani
Gynaecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy
2 shared publications - Giovanni Scambia
Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
2 shared publications - Innocenza Palaia
Department of Maternal and Child Health and Urological Sciences Policlinico Umberto I, Sapienza University of Rome Rome Italy
2 shared publications - Violante Di Donato
Department of Maternal and Child Health and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, 00185 Rome, Italy
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (3)
Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey
Palaia I, et al. J Gynecol Oncol. 2024 Mar;35:e70. https://doi.org/10.3802/jgo.2024.35.e70
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (3)
Open AccessHormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey
Palaia I, et al. J Gynecol Oncol. 2024 Mar;35:e70. https://doi.org/10.3802/jgo.2024.35.e70
- Open Access
- 4 April 2020
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 7 (1) , 1-8
A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer
Purpose: This study aims to estimate the cost-minimization strategy of a preventive testing strategy destined to relatives of patients with BRCA mutated cancer versus a no test strategy in Italia. Methods: A BRCA testing pathway was designed by a panel of experts based on the MSTM Excel (2010) tool; the analysis was carried out considering the perspective of the Italian National Health Service. Two alternatives were considered: 1) preventive BRCA testing for relatives of patients affected by ovarian cancer carrying a BRCA1/BRCA2 mutation; 2) no test. Cost and effectiveness data, derived from literature and published sources validated by a Board of experts, were discounted using a discount factor equal to 3%. Probabilistic sensitivity analysis was performed. Results: Considering an average cost of therapy for breast and ovarian cancer major of €90,000.00 per case, the economic impact related to the preventive testing strategy are equal to –€17,814,767.25. The sensitivity analysis confirms these results in the totality of the simulations performed. Conclusions: Preventive genetic testing in relatives of patients affected by ovarian cancer is cost-effective and represents a sustainable cost for the National Healthcare System in Italia, also in the light of its reference values.
- 4 April 2020
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 7 (1) , 1-8
Open AccessA cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer
Purpose: This study aims to estimate the cost-minimization strategy of a preventive testing strategy destined to relatives of patients with BRCA mutated cancer versus a no test strategy in Italia. Methods: A BRCA testing pathway was designed by a panel of experts based on the MSTM Excel (2010) tool; the analysis was carried out considering the perspective of the Italian National Health Service. Two alternatives were considered: 1) preventive BRCA testing for relatives of patients affected by ovarian cancer carrying a BRCA1/BRCA2 mutation; 2) no test. Cost and effectiveness data, derived from literature and published sources validated by a Board of experts, were discounted using a discount factor equal to 3%. Probabilistic sensitivity analysis was performed. Results: Considering an average cost of therapy for breast and ovarian cancer major of €90,000.00 per case, the economic impact related to the preventive testing strategy are equal to –€17,814,767.25. The sensitivity analysis confirms these results in the totality of the simulations performed. Conclusions: Preventive genetic testing in relatives of patients affected by ovarian cancer is cost-effective and represents a sustainable cost for the National Healthcare System in Italia, also in the light of its reference values.
- Open Access
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (6) , e92
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups
Bogani G, et al. J Gynecol Oncol. 2019 Jun;31:e92. https://doi.org/10.3802/jgo.2020.31.e92
- 1 January 2020
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 31 (6) , e92
Open AccessImpact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups
Bogani G, et al. J Gynecol Oncol. 2019 Jun;31:e92. https://doi.org/10.3802/jgo.2020.31.e92
- 20 June 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18_suppl) , 5532
Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Preliminary activity results of the MITO-2 randomized multicenter trial
5532 Background: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III study comparing the effect on progression-free survival of carboplatin/paclitaxel versus c...
- 20 June 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18_suppl) , 5532
Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Preliminary activity results of the MITO-2 randomized multicenter trial
5532 Background: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III study comparing the effect on progression-free survival of carboplatin/paclitaxel versus c...
- 19 August 1993
- Published by Wiley in International Journal of Cancer
- Vol. 55 (1) , 122-127
Characterization of cytotoxic activity of saporin anti‐gp185/HER‐2 immunotoxins
The oncogene HER-2/neu encodes a trans-membrane receptor of 185 kDa with tyrosine-kinase activity. Over-expression of this molecule has been reported in a significant proportion of human breast and ovarian carcinomas, characterized by a poor clinical prognosis. Two monoclonal antibodies (MAbs), recognizing distinct epitopes of the gp 185 extracellular domain, have been utilized in the present study for the production of immunotoxins (ITs) by conjugation to the type-1 RIP (ribosome-inactivating protein) plant toxin saporin 6 (SAP). These ITs have been shown to retain tumor-specificity and specifically to inhibit protein synthesis in the gp 185HER-2(+) SK-BR-3 breast-carcinoma cell line with IC50 values lower then I nM. Kinetics of the cytotoxic activity of the ITs are characterized by a slow rate, since incubation times ranging from 24 to 60 hr, depending on the different degree of expression of the receptor, are required to determine > 90% inhibition in the incorporation of radiolabeled leucine. However, the cytotoxic activity of these ITs, as evaluated by a more sensitive clonogenic assay, appears highly potent, since we have observed that 3 to 4 logs of cells are killed upon exposure to the ITs for short times at concentrations ranging from 1 to 5 × 10−8 M.
- 19 August 1993
- Published by Wiley in International Journal of Cancer
- Vol. 55 (1) , 122-127
Characterization of cytotoxic activity of saporin anti‐gp185/HER‐2 immunotoxins
The oncogene HER-2/neu encodes a trans-membrane receptor of 185 kDa with tyrosine-kinase activity. Over-expression of this molecule has been reported in a significant proportion of human breast and ovarian carcinomas, characterized by a poor clinical prognosis. Two monoclonal antibodies (MAbs), recognizing distinct epitopes of the gp 185 extracellular domain, have been utilized in the present study for the production of immunotoxins (ITs) by conjugation to the type-1 RIP (ribosome-inactivating protein) plant toxin saporin 6 (SAP). These ITs have been shown to retain tumor-specificity and specifically to inhibit protein synthesis in the gp 185HER-2(+) SK-BR-3 breast-carcinoma cell line with IC50 values lower then I nM. Kinetics of the cytotoxic activity of the ITs are characterized by a slow rate, since incubation times ranging from 24 to 60 hr, depending on the different degree of expression of the receptor, are required to determine > 90% inhibition in the incorporation of radiolabeled leucine. However, the cytotoxic activity of these ITs, as evaluated by a more sensitive clonogenic assay, appears highly potent, since we have observed that 3 to 4 logs of cells are killed upon exposure to the ITs for short times at concentrations ranging from 1 to 5 × 10−8 M.